Advice
Recommended for restricted use within NHS Scotland.
RECOMMENDATION
Bexarotene is recommended for use in Scotland as a second line treatment for patients with advanced (stages IIb or III) cutaneous T-cell lymphoma. Bexarotene treatment should normally be initiated and supervised by haematologists, dermatologists or oncologists and used for patients who have proved refractory both to local skin directed therapy and to at least one systemic treatment.
Download detailed advice18KB (PDF)
Medicine details
- Medicine name:
- Bexarotene (Targretin®)
- SMC ID:
- 14/02
- Indication:
- Skin manifestations of advanced stage cutaneous T-cell lymphoma
- Pharmaceutical company
- Ligland/Elan
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Restricted
- Date advice published
- 08 November 2002